Literature DB >> 36100802

Curcumin nanoparticles: the topical antimycotic suspension treating oral candidiasis.

Souzy Kamal Anwar1, Sarah Nasser Abd Elmonaem2, Eglal Moussa2, Aliaa Gamaleldin Aboulela3, Marwa Morsy Essawy4,5.   

Abstract

Phytotherapeutics is widely used nowadays as an alternative to the current antifungal drugs to reduce their side effects. Curcumin, with its wide therapeutic array as antioxidant and anti-inflammatory agent, is one of the natural compounds that ha..s an antifungal effect, especially when being used at nanoscale to increase its bioavailability. Our research aimed to evaluate clinically and microbiologically the effect of using topical nanocurcumin suspension to treat oral candidiasis. After 4 days from induction of oral candidiasis (baseline), we randomly divided 39 female BALB/c mice into three groups of 13 animals; nanocurcumin, nystatin, and sham groups. All animals in nanocurcumin and nystatin groups received topical treatment twice daily for 10 days. Then, we performed clinical and microbiological evaluations at baseline, day 5, and day 10. By the end of treatment, our results revealed that nanocurcumin promoted a significant reduction in the number of candida colonies. There was no statistically significant difference neither clinically nor microbiologically between nanocurcumin and nystatin groups. In conclusion, nanocurcumin has a good antifungal effect as nystatin, however, its therapeutic efficacy takes a longer time to appear than nystatin. The enhanced bioavailability of curcumin at the nanoscale qualifies this nano-herb as a promising alternative therapy for oral candidiasis, evading nystatin-associated morbidity.
© 2022. The Author(s).

Entities:  

Keywords:  Nanocurcumin; Nanotechnology; Nystatin; Oral candidiasis

Year:  2022        PMID: 36100802     DOI: 10.1007/s10266-022-00742-4

Source DB:  PubMed          Journal:  Odontology        ISSN: 1618-1247            Impact factor:   2.885


  32 in total

Review 1.  Antifungal agents and liver toxicity: a complex interaction.

Authors:  Frank P Tverdek; Diamantis Kofteridis; Dimitrios P Kontoyiannis
Journal:  Expert Rev Anti Infect Ther       Date:  2016-06-23       Impact factor: 5.091

2.  Oral colonization by yeasts in HIV-positive patients in Brazil.

Authors:  Juliana C Junqueira; Simone F G Vilela; Rodnei D Rossoni; Júnia O Barbosa; Anna Carolina B P Costa; Vanessa M C Rasteiro; Jamal M A H Suleiman; Antonio Olavo C Jorge
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2012 Jan-Feb       Impact factor: 1.846

Review 3.  Clinical hepatotoxicity associated with antifungal agents.

Authors:  Ioannis Kyriakidis; Athanasios Tragiannidis; Silke Munchen; Andreas H Groll
Journal:  Expert Opin Drug Saf       Date:  2016-12-16       Impact factor: 4.250

Review 4.  Antifungal therapy with an emphasis on biofilms.

Authors:  Christopher G Pierce; Anand Srinivasan; Priya Uppuluri; Anand K Ramasubramanian; José L López-Ribot
Journal:  Curr Opin Pharmacol       Date:  2013-09-04       Impact factor: 5.547

5.  Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.

Authors:  David L Horn; Dionissios Neofytos; Elias J Anaissie; Jay A Fishman; William J Steinbach; Ali J Olyaei; Kieren A Marr; Michael A Pfaller; Chi-Hsing Chang; Karen M Webster
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

Review 6.  Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins.

Authors:  Ajaikumar B Kunnumakkara; Preetha Anand; Bharat B Aggarwal
Journal:  Cancer Lett       Date:  2008-05-13       Impact factor: 8.679

Review 7.  Antioxidant and anti-inflammatory properties of curcumin.

Authors:  Venugopal P Menon; Adluri Ram Sudheer
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

8.  Curcumin as a promising antifungal of clinical interest.

Authors:  C V B Martins; D L da Silva; A T M Neres; T F F Magalhães; G A Watanabe; L V Modolo; A A Sabino; A de Fátima; M A de Resende
Journal:  J Antimicrob Chemother       Date:  2008-11-26       Impact factor: 5.790

Review 9.  Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs.

Authors:  Christopher G Pierce; Jose L Lopez-Ribot
Journal:  Expert Opin Drug Discov       Date:  2013-06-06       Impact factor: 6.098

Review 10.  Antifungal Resistance in Dermatology.

Authors:  Varadraj Pai; Ajantha Ganavalli; Naveen Narayanshetty Kikkeri
Journal:  Indian J Dermatol       Date:  2018 Sep-Oct       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.